Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance.
暂无分享,去创建一个
Aleksandra Karolak | Katarzyna A Rejniak | Judith Pérez-Velázquez | Jana L Gevertz | J. Gevertz | K. Rejniak | A. Karolak | J. Pérez-Velázquez
[1] M. Heymann,et al. The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets , 2011, Sarcoma.
[2] M. Gottesman,et al. The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance , 2013 .
[3] William Pao,et al. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells , 2015, Cancer informatics.
[4] Jeff Gore,et al. Turning ecology and evolution against cancer , 2014, Nature Reviews Cancer.
[5] M. Bui,et al. Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials. , 2015, Medical hypotheses.
[6] Gibin G Powathil,et al. Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model. , 2012, Journal of theoretical biology.
[7] F. Baquero,et al. Ecology and Evolution as Targets: the Need for Novel Eco-Evo Drugs and Strategies To Fight Antibiotic Resistance , 2011, Antimicrobial Agents and Chemotherapy.
[8] Ying Zhang. Persisters, persistent infections and the Yin–Yang model , 2014, Emerging Microbes & Infections.
[9] M. Gottesman,et al. The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.
[10] Mina J. Bissell,et al. The perivascular niche regulates breast tumor dormancy , 2013, Nature Cell Biology.
[11] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[12] A. Pisco,et al. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me' , 2015, British Journal of Cancer.
[13] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[14] P. Karran. Mechanisms of tolerance to DNA damaging therapeutic drugs. , 2001, Carcinogenesis.
[15] Geoffrey R Oxnard,et al. The cellular origins of drug resistance in cancer , 2016, Nature Medicine.
[16] A. Koong,et al. Pancreatic tumors show high levels of hypoxia. , 2000, International journal of radiation oncology, biology, physics.
[17] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[18] Bruce A. Posner,et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.
[19] Junjie Chen,et al. DNA damage tolerance: a double-edged sword guarding the genome. , 2013, Translational cancer research.
[20] T. Schacker,et al. Overcoming pharmacologic sanctuaries , 2013, Current opinion in HIV and AIDS.
[21] R. Kaplan,et al. Niche-to-niche migration of bone-marrow-derived cells. , 2007, Trends in molecular medicine.
[22] P. Steeg,et al. The Biology of Metastasis to a Sanctuary Site , 2007, Clinical Cancer Research.
[23] Lothar Lilge,et al. The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.
[24] Martin A. Nowak,et al. Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy , 2014, PLoS Comput. Biol..
[25] K. Cimprich,et al. DNA damage tolerance: when it's OK to make mistakes. , 2009, Nature chemical biology.
[26] J. Bigger. Synergic action of penicillin and sulphathiazole on Bacterium typhosum. , 1946, Lancet.
[27] John D Gordan,et al. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. , 2007, Cancer cell.
[28] Z. Werb,et al. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.
[29] E. Friedberg. Suffering in silence: the tolerance of DNA damage , 2005, Nature Reviews Molecular Cell Biology.
[30] Katarzyna A Rejniak,et al. Limiting the Development of Anti-Cancer Drug Resistance in a Spatial Model of Micrometastases , 2016, bioRxiv.
[31] G. Getz,et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.
[32] G. Giaever,et al. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. , 2013, Chemistry & biology.
[33] L. Kleinberg,et al. Unsanctifying the sanctuary: challenges and opportunities with brain metastases. , 2015, Neuro-oncology.
[34] Zhenyu Jin,et al. Bacteria differently deploy type-IV pili on surfaces to adapt to nutrient availability , 2016, npj Biofilms and Microbiomes.
[35] Dominik Wodarz,et al. Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. , 2007, Theoretical population biology.
[36] F. Michor,et al. Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.
[37] Chih-kuan Tung,et al. Acceleration of Emergence of Bacterial Antibiotic Resistance in Connected Microenvironments , 2011, Science.
[38] Orkun S. Soyer,et al. Bacterial Drug Tolerance under Clinical Conditions Is Governed by Anaerobic Adaptation but not Anaerobic Respiration , 2014, Antimicrobial Agents and Chemotherapy.
[39] Mark A. J. Chaplain,et al. Towards Predicting the Response of a Solid Tumour to Chemotherapy and Radiotherapy Treatments: Clinical Insights from a Computational Model , 2013, PLoS Comput. Biol..
[40] Denis Wirtz,et al. Hypoxia and the extracellular matrix: drivers of tumour metastasis , 2014, Nature Reviews Cancer.
[41] H M Byrne,et al. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. , 2000, Mathematical biosciences.
[42] Robert A Gatenby,et al. A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.
[43] D. Lyden,et al. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.
[44] Miles A. Miller,et al. Advances in measuring single-cell pharmacology in vivo. , 2015, Drug discovery today.
[45] Damien J. Ferraro,et al. Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer , 2011, Clinical Cancer Research.
[46] Maciej Swat,et al. Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. , 2015, Seminars in cancer biology.
[47] Mary Ellen Wiltrout,et al. Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance , 2009, Microbiology and Molecular Biology Reviews.
[48] Vittorio Cristini,et al. Understanding Drug Resistance in Breast Cancer with Mathematical Oncology , 2014, Current Breast Cancer Reports.
[49] B. Baguley. Multiple Drug Resistance Mechanisms in Cancer , 2010, Molecular biotechnology.
[50] Greg M. Thurber,et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo , 2013, Nature Communications.
[51] W. Nierman,et al. The In vitro Antibiotic Tolerant Persister Population in Burkholderia pseudomallei is Altered by Environmental Factors , 2015, Front. Microbiol..
[52] Zahra Aminzare,et al. Emergence of Anti-Cancer Drug Resistance: Exploring the Importance of the Microenvironmental Niche via a Spatial Model , 2014, 1412.0780.
[53] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[54] Z. Werb,et al. The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.
[55] Robert H. Austin,et al. An analogy between the evolution of drug resistance in bacterial communities and malignant tissues , 2011, Nature Reviews Cancer.
[56] M. Barcellos-Hoff,et al. The evolution of the cancer niche during multistage carcinogenesis , 2013, Nature Reviews Cancer.
[57] S. Carr,et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages , 2014, Nature Cell Biology.
[58] W. Dalton,et al. The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance , 2008, Clinical Cancer Research.
[59] S. Menchón. The Effect of Intrinsic and Acquired Resistances on Chemotherapy Effectiveness , 2015, Acta Biotheoretica.
[60] L. Vermeulen,et al. Cancer stem cell niche: the place to be. , 2011, Cancer research.
[61] Cyrus M. Ghajar. Metastasis prevention by targeting the dormant niche , 2015, Nature Reviews Cancer.
[62] K. Lewis. Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.
[63] B. Perthame,et al. Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.
[64] Doron Levy,et al. The dynamics of drug resistance: a mathematical perspective. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[65] Marco Foiani,et al. Regulation of DNA repair throughout the cell cycle , 2008, Nature Reviews Molecular Cell Biology.
[66] R. Bristow,et al. Tumor hypoxia as a driving force in genetic instability , 2013, Genome Integrity.
[67] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.